BioWorld MedTech

April 29, 2011

Deals roundup: Toshiba Medical plans to buy Vital Images for about $273M

Toshiba Medical Systems (Tokyo) reported that it would buy Vital Images (Minneapolis) for $18.75 a share, or roughly $273 million in the aggregate, through a cash tender offer followed by a merger. (Medical Device Daily) Read More

HexaPOD offers greater accuracy in cancer treatment

International report: Varian Medical reports Chinese approval of its TrueBeam system

Washington roundup: FDAer hints agency concerned about fail-safe wireless health

Financings roundup: Cianna Medical closes $12M in Series B round of funding

MDD's food for med-tech thought

Agreements/contracts: Proven Process to design components of Titan's Amadeus

HIT roundup: OraMetrix selects Camstar platform for future growth

Restructuring roundup: Medtronic laying off 268 in Twin Cities

Patent watch: AquaStar snags patent for enzyme testing platform

People in the News

Med-Tech Notes

Court Report: Palomar files patent lawsuit against Candela

Product Briefs

MDD's Diagnostic Extra

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld

Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...

3D rendering of skin cells and elastin with collagen layer

First-in-class pan-inflammasome blocker for hidradenitis suppurativa

BioWorld Science

Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.

Illustration of cancer cell in crosshairs being destroyed

RX-10616 improves radiotherapy efficacy in HNSCC

BioWorld Science

Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...

CROI 2026: Neurodegeneration, the challenge of aging with HIV

BioWorld

Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...